

Relentless. Passionate. Focused.™

October 2018




Forward Looking Statements

This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiary, together, unless context otherwise requires, 'Kiniksa," "we" or our). In some cases, you can identify forward looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our strategy, plans and timing for initiation of new clinical trials, potential designs of our new clinical trials, proposed indications for the investigation of our product candidates, plans and timing to report clinical trial data, timing for the initiation of clinical trial sites, plans and timing for the submission of investigational new drug and other applications and submissions to regulatory authorities, and plans and timing to advance additional pipeline programs into clinical trials.

These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including without limitation the important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 7, 2018 and our other reports subsequently filed with the SEC. These forward-looking statements reflect various assumptions of Kiniksa's management that may or may not prove to be correct. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements.

This presentation also contains estimates, projections, and other information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, clinical trials, studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

Except as otherwise indicated, this presentation speaks as of the date of this presentation. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.



KINIKSA

A company with a sequential pipeline, FIRMLY rooted in strong biologic rationale or validated mechanisms, potential for multiple indications, and designed to deliver near-, mid- and long-term value The Kiniksa senior team has extensive experience in drug development and commercialization of valuable therapies

Sanj K. Patel Chairman & Chief Executive Officer

Steve Mahoney President & Chief Operating Officer

> John Paolini Chief Medical Officer

Christine Maurer SVP Program Management

> **Carsten Boess** Corporate Affairs


Chris Heberlig Chief Financial Officer

Eben Tessari Chief Business Officer



Building a fully-integrated global biopharmaceutical company

Discovering, acquiring, developing and commercializing life-changing therapies for debilitating diseases



Focus on the Patients

Rapid Product Development


Expand Existing Portfolio Across Multiple Indications

Build Core Capability in Autoimmune and Autoinflammatory Diseases

Identify New Products



Strategic approach to building a portfolio



KINIKSA

Identified pockets of unmet need ripe for innovation across a range of autoinflammatory & autoimmune diseases

•

•

•


•

A sequential pipeline across various stages of development

Designed to deliver near-, mid- and long-term value

Program & Target	Lead Indication	Preclin	Pha 1	se 2	3	Status and Anticipated Next Milestone	Rights
Rilonacept¹ IL-1α & IL-1β	Recurrent Pericarditis					 Expect to report additional data from ongoing open-label Phase 2 proof-of-concept trial in 2H 2018 Plan to advance to a pivotal Phase 3 trial in 2H 2018 	Worldwide (excluding MENA)
Mavrilimumab GM-CSFRα	Giant Cell Arteritis					 Plan to advance to a Phase 2 proof-of-concept trial in 2H 2018 	Worldwide
KPL-716 OSMRβ	Prurigo Nodularis / Atopic Derm					 Plan advancement into multiple chronic pruritic diseases, including prurigo nodularis Ongoing repeat single-dose Phase 1b trial in subjects with AtD 	Worldwide
KPL-045² CD30L	Autoimmune					 IND filing planned for 2H 2019 	Worldwide
KPL-404² CD40	Autoimmune					• IND filing planned for 2H 2019	Exclusive Option for Worldwide

1) Rilonacept (ARCALYST®) is approved and marketed for cryopyrin-associated periodic syndrome, in the United States by Regeneron. We will assume the rights to this indication upon receiving approval for rilonacept in the recurrent pericarditis indication; 2) We are planning IND-enabling studies for both KPL-045 and KPL-404 in T-cell-dependent, B-cell-mediated diseases, such as pemphigus/pemphigoid, myasthenia gravis, or graft versus host disease.



An opportunity in an inflammatory cardiovascular disease with established proof-of-concept and no currently-approved therapies

Lead Indication	Recurrent Pericarditis
Patient Population ¹	 ~90k patients in the US experience an acute incident of pericarditis per year ~3k refractory patients and ~9k who are not well-managed on existing therapies in the US Incremental opportunity as a steroid-sparing agent and to treat Post Pericardiotomy and Dressler Syndromes
Mechanism of Action ²	 IL-1α and IL-1β cytokine trap Inhibition of IL-1 has been shown to be instrumental in the resolution of recurrent pericarditis
Competition ³	 No currently-approved therapies Differentiated from both existing marketed IL-1 agents
Clinical Development	 Expect to report additional data from ongoing open-label Phase 2 proof-of-concept trial in 2H 2018 Plan to advance to a pivotal Phase 3 trial in 2H 2018

1) UptoDate, Trinity Partners, Mayo Clin Proc. 2010;85 (6): 572-593; New Diagnostic Criteria for Acute Pericarditis: A Cardiac MRI Perspective, 2015 American College of Cardiology; 2) Brucato et al. JAMA. 2016, 316 (18): 1906-1912; Arcalyst Prescribing Information; 3) Drugs@FDA: Arcalyst Prescribing Information, Ilaris Prescribing Information, Kineret Prescribing Information, Kineret Prescribing Information, Kineret Prescribing Information, Kalsel et al. Anthritis Research & Therapy 2011, 13:R125; Cardiel et al. Arthritis Research & Therapy 2010, 12:R192; Hong KINIKSA 9 October 2018 t al. Lancet Oncol 2014, 15: 656-666 8



The role of IL-1 α signaling in the pathology of recurrent pericarditis and multiple diseases of sterile serosal inflammation

Proof-of-concept in RIP shown by anakinra (daily sc-administered IL-1α and IL-16 blocker) in AIRTRIP study

Anakinra in Patients with Cortico-Dependent Idiopathic Recurrent Pericarditis: A Randomised Double-Blind Placebo-Controlled Withdrawal Trial AIR TRIP = AnakInRa - Treatment of Recurrent

Idiopathic Pericarditis

Antonio Brucato, Massimo Imazio, Silvia Maestroni, Davide Faustino Cumetti, Anna Valenti, Renzo Marcolongo, George Lazaros, Mara Carraro, Fiorenzo Gaita, Gian Luca Erre, Martina Finetti, Marco Gattorno and Alberto Martini.


Patients With Recurrent Pericarditis Free of Relapse in the Double-Blind Withdrawal Phase, From Day 0 to Day 180 After Randomization (Intention-to-Treat Analysis) 1.0 Relapse 8.0 Anakinra Proportion of Patients Free of 6.0 Log-rank P<.001 4.0 2.0 Placebo 0 Ó 30 60 90 120 150 180 Days After Randomization

IL-16-only inhibition does not work in this patient population

heodoropoulou et al. Pediatric Rheumatology 2015, 13(Suppl 1):P155 PEDIATRIC com/content/13/S1/P15 RHEUMATOLOGY POSTER PRESENTATION Open Acces A case of corticosteroid-dependent recurrent pericarditis with different response to two IL-1 blocking agents K Theodoropoulou[®], A von Scheven-Gête, S Bressieux-Degueldre, M Prsa, F Angelini, T Boulos, M Hofer From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases Dresden, Germany. 30 September - 3 October 2015 Introduction months later, while being in complete remission, anaking Recurrent pericarditis (RP) has a controversial nathogenesis was replaced with canakin umab (2mg/kg/dose) due to that crosses infectious, auto-immune and auto-inflammatory patient's intolerance of daily injections. One week later, pathways. It has been suggested that in some cases it might the patient experienced a new episode of pericarditis be an unrecognized auto-inflammatory disease. Recent sturequiring corticotherapy. Two more relapses occured durdies have demonstrated that anakinra, an interleukin-1 ing steroid tapering, after 6 weeks and 2 months, in spite receptor antagonist (IL-1RA), represents an effective treatof the uptitration of canakinumab to 4mg/kg/dose. Anament for the control of corticosteroid-dependent cases. kinra was restarted with prompt clinical and biological remission and prednisone was discontinuated without Objective recurrence of pericarditis. Four weeks later, anakinra was Here we describe a case of cortico-dependent recurrent spaced out every 2 days and a treatment of colchicine was pericarditis with a different response to two IL-1 blocking added. After further 12 weeks follow-up under anakinra agents, anakinra and canakinumab and colchicine, the pericarditis is still in remission Materials and methods Conclusion Case report e describe a c atic therapeutic response to IL-1RA (anakinra) b Results nse to IL-18 monoclonal antiboo A 11-year-old boy was admitted to our hospital with acute mab). This unexpected observation could s precordial pain, orthopnea, fever and increased levels of 1α might have a role in the path acute phase reactants. Acute pericarditis was confirmed by A more precise usefulness of each IL-1 blocking agent echocardiography and a treatment with prednisone was requires confirmation in prospective controlled trials started with prompt clinical improvement. Pericarditis recurred twice during steroid tapering (at 1mg/kg/day and Consent to publish 0.5mg/kg/day respectively). After exclusion of infectious Written informated consent for publication of their clini origin, therapy with anakinra (2mg/kg/day) was estabcal details was obtained from the patient/parent/guardian relative of the patient lished (to avoid long term steroid side effects) followed by dramatic clinical response and normalisation of laborator findings despite tapering and discontinuation of predni sone. Treatment with anakinra was discontinued after 5 months with recurrence of pericarditis one week later Anakinra was resumed with an excellent response. Five x:10.1186/1546-0096-13-S1-P155 Cite this article as: Theodoropoulou et al: A case of conticosteroi endent recurrent percardits with different response to two IL-1 locking agents. Rediatric Rheumatology 2015 13(Suppl 1)P15 ospital (CHUM Lausann http://creativecommons.org/licenses/by/4/0), which permits unrestricted use, distribution, and reproduction in any medium, pro he original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ ubilicdoma/uicens/1/0) applies to the data made available in this anticle, unless otherwise stands. BioMed Central


IL-1 α signature across multiple diseases of sterile serosal inflammation

human reproduction	ORIGINAL ARTICLE Reproductive	genetics
	Association between the interleukin IA (I	
J Res Med Sci. 2014 De	c; 19(12): 1145–1149.	PMCID: PMC4333522
The diagnosti control study	c role of cervico-vaginal fluid interleu	ıkins-1α in endometriosis: A case-
	Imbalance in Cytokines from Pathogenesis of Endometric Justyna Sikora*, Aleksandra Mielczarek-Palac Depatrent of Immunology and Serology, Medical University of	z, Zdzislawa Kondera-Anasz
	n 1 α and tissue-lytic matri ed in ectopic endometrium	
endometri	0515	
endometri	0815	Gut, 1990, 31 , 686–689
Role of in	nterleukin 1 in inflamma 1 production during activ	tory bowel disease –
Role of in	nterleukin 1 in inflamma	tory bowel disease –
Role of in enhanced Epithelial Co Pathogenes	nterleukin 1 in inflamma 1 production during activ ell-Derived IL-1-alpha as a N is	tory bowel disease – ve disease
Role of in enhanced Epithelial Co Pathogenes Fiocchi, Claudio	nterleukin 1 in inflamma 1 production during activ ell-Derived IL-1-alpha as a N is	tory bowel disease – ve disease
Role of in enhanced Epithelial Co Pathogenes Fiocchi, Claudio	nterleukin 1 in inflamma d production during activ ell-Derived IL-1-alpha as a N is stylianou, Eleni	tory bowel disease – ve disease
Role of in enhanced Epithelial Co Pathogenes Fiocchi, Claudio	nterleukin 1 in inflamma d production during activ ell-Derived IL-1-alpha as a N is stylianou, Eleni	tory bowel disease – ve disease
Role of in enhanced Epithelial Co Pathogenes Fiocchi, Claudio	nterleukin 1 in inflamma 1 production during activ ell-Derived IL-1-alpha as a N is stylianou, Eleni erner, Cleveland, OH, United States	tory bowel disease – ve disease
Role of in enhanced Epithelial Co Pathogenes Fiocchi, Claudio	nterleukin 1 in inflamma 1 production during activ ell-Derived IL-1-alpha as a N is stylianou, Eleni erner, Cleveland, OH, United States	tory bowel disease – ve disease





Open-label Phase 2 clinical trial of rilonacept in pericarditis populations






Phase 2 safety and efficacy data in over 550 rheumatoid arthritis subjects in the EU and mechanistic rationale for focusing on high unmet need vasculitides & inflammatory cardiomyopathies

Lead Indication	Giant Cell Arteritis (GCA)
Patient Population ¹	• ~75k - 150k prevalent GCA patients in the US typically treated with steroid; similar prevalence in EU
Mechanism of Action ²	 Monoclonal antibody inhibitor targeting GM-CSFRα Blocks GM-CSF signaling, a key mediator of inflammation and autoimmunity
Competition ³	 Potential first-in-class molecule One FDA approved therapy for GCA but there is still a persistent unmet need
Clinical Development	Plan to advance to a Phase 2 proof-of-concept trial in 2H 2018

1) Chandran et al., Scand J Rheumatol, 2015; Trinity Consulting – HCUP/Medicare Data, Quantitative Survey (n=102 rheumatologists); 2) Sources: Wicks, Roberts, Nature Review Immunology, 2015; Hamilton, Expert Review of Clinical Immunology, 11:4, 457-465; 3) Cortellis,; UpToDate; Correspondence, Trial of Tocilizumab in Giant-Cell Arteritis, NEJM, 2017

GM-CSF implicated in the pathology of giant cell formation by promoting activation, differentiation, survival and proliferation of key cell types

Pathology of GCA



- GM-CSF is critical for the stimulation of hematopoietic progenitor cells in the bone marrow to generate differentiated myeloid-cell progeny (dendritic cells [DCs], neutrophils, eosinophils and monocyte/macrophages)
- GM-CSF enhances trafficking of these cell types through activated endothelium blood vessels, directly contributing to myeloid cell accumulation in blood vessels
- GM-CSF promotes activation, differentiation, survival and proliferation of trafficking monocytes and macrophages as well as resident tissue macrophages in inflamed tissues
- As shown in the diagram, DCs and macrophages are critical in all three stages of GCA pathology; therefore, blockade of GM-CSF with mavrilimumab has significant potential to attenuate both new-onset and relapsing disease
 - In the chronic phase GM-CSF promotes giant cell formation, the hallmark pathologic finding of GCA, from activated macrophages
- Further evidence is provided by data showing elevation of GM-CSF in the lesions of GCA patients

Sources: Weyand, Ann Int Med 121:484, 1994; Watanabe Joint Bone Spine, in press; Wicks, Roberts, Nature Reviews Rheumatology, 2016; Dejaco et al., Nature Reviews Rheumatology, 2017

(INIKSA






A differentiated molecule with potential to treat a variety of pruritic and fibrotic indications

Lead Indications	 Prurigo Nodularis (PN) Atopic Dermatitis (AtD)
Patient Population ¹	 PN: Estimated ~300k patients in the US AtD: Estimated ~1 M moderate-to-severe patients in the US; ~300k of which are eligible for systemic biologics
Mechanism of Action ²	 Monoclonal antibody inhibitor of signaling through OSMRβ OSMRβ is a key receptor subunit used by two inflammatory cytokines, IL-31 and Oncostatin M
Competition ³	 Potential for differentiated efficacy and safety Competitors block either IL-31 or OSM alone
Clinical Development	 Plan advancement into multiple chronic pruritic diseases, including prurigo nodularis Ongoing repeat single-dose Phase 1b trial in subjects with AtD

1)Trinity Consulting - HCUP/Medicare Data 2012/2013; Quantitative Survey (n=100 dermatologists); Dantas, 2015, "Prevalence of dermatoses in dermatologic evaluation requests from patients admitted to a tertiary hospital for 10 years"; Mortz et al., Britis Journal of Dermatology, 2001; 2) Trinity Qualitative Interviews; 3) Simpson et al., N Engl J Med, 2016; Ruzicka et al., N Engl J Med, 2017; Reid et al., 2016 ACR Abstract # 1881; Cortellis


9 October 2018

KPL-716 inhibits IL-31 & OSM signaling through OSMRβ but avoids inhibiting signaling critical to hematopoiesis through OSM/LIFR




KPL-716 demonstrated potential efficacy in two validated primate models of pruritus and inflammation after a single dose

<u>NHP Model of Pruritus¹</u>



A single dose of KPL-716 inhibited pruritic response driven by supraphysiologic levels of IL-31 for over 2 weeks at 3mg/kg

NHP Model of Inflammation¹



Single dose of KPL-716 increased tail withdrawal latency \rightarrow implicates OSMR β in the inflammatory response


KINIKSA

15

KPL-716 placebo-controlled, single-ascending-dose Phase 1a/1b study design

Phase 1a: Normal Healthy Volunteer (n=50)

Phase 1b: Subjects with Atopic Dermatitis (n=32)



Baseline parameters were balanced overall

KPL-716 recipients had more atopic dermatitis flares in the year prior to enrollment, suggesting more unstable disease at baseline compared with placebo

Baseline Demographics/Disease Characteristics: AD	KPL-716 7.5 mg/kg IV	Placebo Pooled IV
Age, mean (SD), years	29.7 (11.2)	41.7 (10.9)
Male, %	50	70
White, %	70	70
Elevated IgE, %	60	60
History of any allergic disease, %	40	60
#AD flares in past year, mean (SD)	28.1 (41.6)	3.7 (3.5)
Body surface area affected by AD, mean (SD)	24.2 (8.0)	34.1 (28.0)
Weekly average WI-NRS, mean (SD)	8.0 (1.3)	8.2 (0.7)
Total EASI, mean (SD)	19.9 (7.6)	25.3 (14.1)
Total SCORAD, mean (SD)	66.7 (10.7)	60.7 (13.7)
IGA=3, %	80	80
IGA=4, %	20	20

Baseline is defined as the last measurement prior to dosing, AD = atopic dermatitis, IV = intravenous, IGA = Investigator's Global Assessment (severity scale), WI-NRS = Worst Itch Numerical Rating Scale, EASI = Eczema Area and Severity Index, SCORAD = Scoring atopic dermatitis (severity scale) 17



KPL-716 was well-tolerated

- No Deaths
- No SAEs
- No Discontinuations due to AEs
- No Infusion Reactions
- No Injection Site Reactions

Normal Healthy Volunteers

- No Thrombocytopenia
- No Peripheral Edema
- No Conjunctivitis

• Drug-Related Treatment Emergent Adverse Events (DR-TEAEs) infrequent and not related to dose

KINIKSA

		KPL-716 (IV)	l.		Placebo (IV)	KPL-71	Placebo (SC)	
AE	1.5 mg/kg n=6	5 mg/kg 10 mg/k n=6 ⁿ⁼⁶		20 mg/kg n=6	Pooled n=8	1.5 mg/kg 360 mg n=6 n=7		Pooled n=5
DR-TEAE	0	Mild headache (n=1)	0	0	0	Mild flushing (n=1)	Mild anemia (n=1)	0

Subjects with Atopic Dermatitis


AE		KPL-716 (IV))	Placebo (IV)	KPL-716 (SC)	Placebo (SC)
	0.3 mg/kg n=3	1.5 mg/kg n=3	7.5 mg/kg n=10	Pooled n=10	1.5 mg/kg n=4	Pooled n=2
DR-TEAE+	0	Mild headache (n=1), Decreased appetite (n=1)	Moderate dizziness (n=1)	Mild somnolence (n=1)	Mild dizziness (n=1)	0
AD flare	1	0	2	3	0	0
Study day of AD flare	7	N/A	14, 20	1, 5, 45	N/A	N/A

⁺The only moderate DR-TEAE occurred after a protocol violation.

9 October 2018

KPL-716 demonstrated dose-dependent elimination consistent with a target mediated drug disposition profile

7.5 mg/kg IV dose level was detectable through at least 8 weeks



Exploratory efficacy endpoints and analysis plan

Efficacy Endpoints:

- Pruritus:
 - Weekly average of daily WI-NRS (worst itch in past 24 hours) collected by daily eDiary
 - Pruritus Visual Analog Scale, a component of SCORAD (average itch in past 3 days) collected at study visits
- Sleep loss VAS:
 - A component of SCORAD (average sleep loss in past 3 nights)
- Eczema Area Severity Index (EASI)

Efficacy Analysis:

- 10 KPL-716 subjects (7.5 mg/kg IV) versus 10 placebo subjects (pooled IV) from baseline to Day 28
- "Last Observation Carried Forward" approach used for data values after rescue medication administered. Subject was considered non-responder after rescue (responder analysis).
 - Two KPL-716: 2 AD flares (d15 and d21)
 - Three placebo: 2 AD flares (d3, d14), 1 anti-histamine use for upper respiratory infection (d26)
- Similar results obtained if data values after rescue medication administration were included or excluded

AD = atopic dermatitis, IV = intravenous, WI-NRS = Worst Itch Numerical Rating Scale, EASI = Eczema Area and Severity Index, SCORAD = Scoring atopic dermatitis (severity scale)


KINIK

Single-dose of KPL-716 reduced pruritus versus placebo over the 28 day monotherapy period

Pruritus Visual Analog Scale (VAS)¹

Weekly Average Worst Itch Numerical Rating Scale (WI-NRS)

KINIKSA




1) VAS = A component of SCORAD In subjects who received rescue medication, last observation was carried forward. Two KPL-716 recipients (d15, d21) and three placebo recipients (d3, d14, d26)

SCORAD = Scoring atopic dermatitis (severity scale)

9 October 2018

50% of KPL-716 recipients demonstrated a ≥ 4-point reduction in weekly average WI-NRS¹ compared to 10% of placebo at Day 28 in the absence of concomitant TCS²



Subject was considered non-responder after rescue. Two KPL-716 recipients (d15, d 21) and three placebo recipients (d3, d14, d26).

KINIKSA

1) WI-NRS = Worst Itch Numerical Rating Scale; 2) TCS = topical corticosteroids 22


9 October 2018

The maximum decrease in WI-NRS¹ at Day 28 in the absence of concomitant TCS² was ≥ 8-points in KPL-716 recipients compared to 4-points in placebo

KPL-716 (7.5mg/kg IV)

Placebo (Pooled IV)


KINIKSA



Subject was considered non-responder after rescue. Two KPL-716 recipients (d15, d 21) and three placebo recipients (d3, d14, d26).

1) WI-NRS = Worst Itch Numerical Rating Scale; 2) TCS = topical corticosteroids


KPL-716 recipients reported reduced sleep loss VAS1 versus placebo over the 28day monotherapy periodSleep Loss VAS1



In subjects who received rescue medication, last observation was carried forward. Two KPL-716 recipients (d15, d 21) and three placebo recipients (d3, d14, d26)

1) VAS = Visual Analog Scale and a component of SCORAD.

Single-dose of KPL-716 reduced atopic dermatitis disease severity versus placebo over the 28 day monotherapy period




In subjects who received rescue medication, last observation was carried forward. Two KPL-716 recipients (d15, d 21) and three placebo recipients (d3, d14, d26).



Signal inhibitor of the CD30/CD30L interaction – a T-cell co-stimulatory receptor involved in activated T-memory function

- Biology important for activated T-memory cell function
- Comprehensive non-clinical package and POM established in models
- Favorable pharmacokinetic profile supports further development
- Preparing for IND enabling studies



A central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity – designed to inhibit CD40/CD40L interaction

- External PoC of CD40 antagonism established by Novartis in autoimmune disease
- Favorable pharmacokinetic profile supports further development
- Preparing for IND enabling studies



A sequential pipeline across various stages of development

Designed to deliver near-, mid- and long-term value

Program & Target	Lead Indication	Preclin	Pha 1	se 2	3	Status and Anticipated Next Milestone	Rights
Rilonacept¹ IL-1α & IL-1β	Recurrent Pericarditis					 Expect to report additional data from ongoing open-label Phase 2 proof-of-concept trial in 2H 2018 Plan to advance to a pivotal Phase 3 trial in 2H 2018 	Worldwide (excluding MENA)
Mavrilimumab GM-CSFRα	Giant Cell Arteritis					 Plan to advance to a Phase 2 proof-of-concept trial in 2H 2018 	Worldwide
KPL-716 OSMRβ	Prurigo Nodularis / Atopic Derm					 Plan advancement into multiple chronic pruritic diseases, including prurigo nodularis Ongoing repeat single-dose Phase 1b trial in subjects with AtD 	Worldwide
KPL-045² CD30L	Autoimmune					 IND filing planned for 2H 2019 	Worldwide
KPL-404² CD40	Autoimmune					• IND filing planned for 2H 2019	Exclusive Option for Worldwide

1) Rilonacept (ARCALYST®) is approved and marketed for cryopyrin-associated periodic syndrome, in the United States by Regeneron. We will assume the rights to this indication upon receiving approval for rilonacept in the recurrent pericarditis indication; 2) We are planning IND-enabling studies for both KPL-045 and KPL-404 in T-cell-dependent, B-cell-mediated diseases, such as pemphigus/pemphigoid, myasthenia gravis, or graft versus host disease.

5 pipeline programs

> 180 issued patents

~\$490m gross proceeds raised to date

~\$359m cash and cash equivalents as of 6/30/18 (no debt)

Bermuda based corporate structure

Kiniksa at a glance

Every Second Counts!



Every Second Counts!TM

